Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

March 12, 2024

https://www.globenewswire.com/news-release/2024/03/12/2844624/0/en/Artelo-Biosciences-Selected-as-a-Finalist-in-Johnson-Johnson-s-Innovation-Challenge.html

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE:JNJ) Innovation Challenge. This invitation-only event seeks novel approaches to treating atopic dermatitis from around the world. Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.